These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Randomised, double-blind, placebo-controlled study of pivagabine in neurasthenia.
    Author: Pizzolato G, Cagnin A, Mancia D, Caffarra P, Avanzi S, Copelli S, Ciappina C, Lo Presti F, Spilimbergo PG, D'Antonio E, Di Costanzo E, Matrango M, Pastres P, Urbani PP, Signorino M, Simoncelli M, Provinciali L, Regnicolo L, Albano C, Roccatagliata G, Rubino V, Cultrera S, Fracassi M.
    Journal: Arzneimittelforschung; 1997 Nov; 47(11A):1329-31. PubMed ID: 9450159.
    Abstract:
    One hundred and eighteen patients with neurasthenia, as defined by ICD 10 (International Classification of Diseases), participated in a randomised, double-blind, placebo-controlled trial of pivagabine (4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid, CAS 69542-93-4, Tonerg). Pivagabine 1800 mg/d was administered orally for four weeks. At the end of the trial, active medication was significantly superior to placebo on the Clinical Global Impression (CGI) improvement of illness scale. In addition, pivagabine treatment reduced the physical and mental fatigability of patients, and increased their sense of well-being.
    [Abstract] [Full Text] [Related] [New Search]